Discovery Laboratories, which is developing Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants, has changed its name to Windtree Therapeutics, the company said.
CEO Craig Fraser, who was appointed in February 2016, commented, “Today marks a new direction in the pursuit of our mission to save and improve lives, beginning with the care of the most fragile of patients – premature infants. As we look to the future, it seems only fitting that recent changes in our leadership and approach be coupled with a name and image most reflective of our laser focus on respiratory disease, our commitment to patients, and our determination to build a valuable venture. We believe this rebranding effort will allow us to better convey our focus and vision for the Company and for our products, as well as reflect the fresh, new direction we are taking the Company.”
In December 2015, Discovery Labs announced the initiation of a Phase 2b clinical trial of Aerosurf, which is expected to enroll up to 240 premature infants. Windtree says that the trial is expected to complete enrollment by the end of the year, with top-line results expected in the first quarter of 2017.
Read the Windtree Therapeutics press release.
